Health Care·Biotechnology·$5.5B
MIRUM Pharmaceutical is a biotechnology company focused on developing innovative therapies for rare diseases. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, particularly in liver diseases.
EPS
Earnings per share is a key indicator of profitability and financial health, and investors will be looking for signs of improvement.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
-276.30%
Avg Stock Reaction
+0.30%
In Q4-2025, MIRUM reported an EPS of $-0.47, significantly missing the estimate of $0.02. The stock reacted positively, gaining 1.06% the following day despite the disappointing earnings.
Management Promises & Guidance
Analysts expect MIRUM to report a loss of $-0.39 per share on revenues of $149 million for Q1-2026. The company has a mixed track record of beating earnings estimates, which adds uncertainty to investor expectations.
Bull Case
If MIRUM can beat the EPS estimate and show strong revenue growth, it could signal a turnaround in performance and boost investor confidence.
Bear Case
A larger-than-expected loss or lower revenue could raise concerns about the company's financial stability and future growth prospects.
EPS
$-0.39Earnings per share is a key indicator of profitability and financial health, and investors will be looking for signs of improvement.
Revenue
$149MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will MIRUM's EPS exceed the consensus estimate of $-0.39?
A surprise in EPS could significantly impact investor sentiment and stock performance.
Q2
What revenue figure will MIRUM report, and how does it compare to the $149 million consensus?
Revenue performance is critical for assessing the company's market position and growth potential.
Why consensus could be wrong
The consensus may be underestimating MIRUM's potential for revenue growth due to recent product developments that have not been fully factored into projections.
Supporting Evidence
The company has a history of surprising on EPS, with a 63% beat rate over the last eight quarters.
Recent product advancements may not be reflected in current revenue estimates.
The stock has shown resilience in the face of earnings misses, suggesting underlying strength.
Key Risk
If revenue exceeds $155 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is focused on whether MIRUM can show signs of recovery after recent disappointing earnings.
Bull Confirmed If
An EPS of $-0.30 or better, along with revenue exceeding $155 million, would confirm the bull case.
Bear Confirmed If
An EPS worse than $-0.60 and revenue below $141 million would confirm the bear case.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If MIRUM beats expectations, history suggests the stock could rise by around 1.04%, confirming a positive turnaround narrative.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of approximately 0.93%, reinforcing concerns about the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026